Study to Assess Droxidopa in Treatment of Neurogenic Orthostatic Hypotension in Patients With Parkinson's Disease

Systolic blood pressure is transiently and minimally decreased in healthy individuals upon
standing. Normal physiologic feedback mechanisms work through neurally-mediated pathways to
maintain the standing blood pressure, and thus maintain adequate cerebral perfusion. The
compensatory mechanisms that regulate blood pressure upon standing are dysfunctional in
subjects with orthostatic hypotension (OH), a condition that may lead to inadequate cerebral
perfusion with accompanying symptoms of syncope, dizziness or lightheadedness, unsteadiness
and blurred or impaired vision, among other symptoms.

Orthostatic hypotension may be a severely disabling condition which can seriously interfere
with the quality of life of afflicted subjects. Currently available therapeutic options
provide some symptomatic relief in a subset of subjects, but are relatively ineffective and
are often accompanied by severe side effects that limit their usefulness. Support garments
(tight-fitting leotard) may prove useful in some subjects, but is difficult to don without
family or nursing assistance, especially for older subjects. Midodrine, fludrocortisone,
methylphenidate, ephedrine, indomethacin and dihydroergotamine are among some of the
pharmacological interventions that have been used to treat orthostatic hypotension, although
only midodrine is specifically approved for this indication. The limitations of these
currently available therapeutic options, and the incapacitating nature and often progressive
downhill course of disease, point to the need for an improved therapeutic alternative.

Symptomatic OH in patients with Parkinson's disease is thought to be a consequence of
norepinephrine depletion leading to low systolic blood pressure (SBP) and
cerebral-hypoperfusion (reduced blood flow to the brain). Therapy with droxidopa results in
increased levels of norepinephrine which should lead to improved SBP and cerebral perfusion
thereby reducing the signs and symptoms of NOH. The present study will evaluate the clinical
benefit in NOH patients with PD treated with droxidopa compared to those treated with
placebo.

Participation in the study will last a maximum of 14 weeks consisting of a 2 week (maximum)
screening/baseline period; a 2 week (maximum) double-blind dose titration; an 8 week
double-blind placebo-controlled treatment period; and a 2 week follow-up period. An
extension study is also available to continue treatment if determined appropriate by the
study doctor. This Study is NCT01132326 sponsored by Chelsea Therapeutics and is enrolling
by invitation only.

Droxidopa:

Droxidopa [also, known as L-threo-3,4-dihydroxyphenylserine, L-threo-DOPS, or L-DOPS] is the
International non-proprietary name (INN) for a synthetic amino acid precursor of
norepinephrine (NE), which was originally developed by Sumitomo Pharmaceuticals Co.,
Limited, Japan. It has been approved for use in Japan since 1989. Droxidopa has been shown
to improve symptoms of orthostatic hypotension that result from a variety of conditions
including Shy Drager syndrome (Multiple System Atrophy), Pure Autonomic Failure, and
Parkinson's disease. There are four stereoisomers of DOPS; however, only the
L-threo-enantiomer (droxidopa) is biologically active. Stereoisomers and enantiomers are
compounds that have the same chemical elements; however, they may react differently as the
elements are positioned in different locations.

The exact mechanism of action of droxidopa in the treatment of symptomatic NOH has not been
precisely defined; however, its NE replenishing properties with concomitant recovery of
decreased noradrenergic activity are considered to be of major importance.

Droxidopa has been marketed in Japan since 1989. Data from clinical studies and
post-marketing surveillance programs conducted in Japan show that the most commonly reported
adverse drug reactions with droxidopa are increased blood pressure, nausea, and headache. In
clinical studies, the prevalence and severity of droxidopa adverse effects appear to be
similar to those reported by the placebo control arm.

Inclusion criteria:

1. 18 years or over

2. Clinical diagnosis of Parkinson's disease

3. Clinical diagnosis of symptomatic neurogenic orthostatic hypotension

At their baseline visit (Visit 2), patients must demonstrate:

- a score of at least 3 or greater on the OHQ composite

- a score of at least 3 or greater on the clinician CGI-S

- a fall of at least 20 mmHg in their systolic blood pressure, or 10 mmHg in their
diastolic blood pressure, within 3 minutes of standing 4. Provide written informed
consent to participate in the study and understand that they may withdraw their
consent at any time without prejudice to their future medical care

Exclusion Criteria:

1. Score of 23 or lower on the mini-mental state examination (MMSE)

2. Concomitant use of vasoconstricting agents for the purpose of increasing blood
pressure;

- Patients taking vasoconstricting agents such as ephedrine, dihydroergotamine, or
midodrine must stop taking these drugs at least 2 days or 5 half-lives (whichever is
longer) prior to their baseline visit (Visit 2) and throughout the duration of the
study

3. Concomitant use of anti-hypertensive medication for the treatment of essential
hypertension

4. Have changed dose, frequency or type of prescribed medication, within two weeks of
baseline visit (Visit 2) with the following exceptions:

- Vasoconstricting agents such a ephedrine, dihydroergotamine, or midodrine

- Short courses (less than 2 weeks) of medications or treatments that do not
interfere with, or exacerbate the patient's condition under study (e.g.
antibiotics)

5. Known or suspected alcohol or substance abuse within the past 12 months (DSM-IV
definition of alcohol or substance abuse)

6. Women who are pregnant or breastfeeding

7. Women of child bearing potential (WOCP) who are not using at least one method of
contraception with their partner

8. Male patients who are sexually active with a woman of child bearing potential (WOCP)
and not using at least one method of contraception

9. Untreated closed angle glaucoma, or treated closed angle glaucoma that, in the
opinion of an ophthalmologist, might result in an increased risk to the patient

10. Sustained severe hypertension (BP ≥ 180 mmHg systolic or ≥ 110 mmHg diastolic in the
seated or supine position which is observed in 3 consecutive measurements over an
hour)

11. Any significant uncontrolled cardiac arrhythmia

12. History of myocardial infarction, within the past 2 years

13. Current unstable angina

14. Congestive heart failure (NYHA Class 3 or 4)

15. Diabetic autonomic neuropathy

16. History of cancer within the past 2 years other than a successfully treated,
non-metastatic cutaneous squamous cell or basal cell carcinoma or cervical cancer in
situ

17. Gastrointestinal condition, which in the Investigator's judgment, may affect the
absorption of study drug (e.g. ulcerative colitis, gastric bypass)

18. Any major surgical procedure within 30 days of the baseline visit (Visit 2)

19. Previously treated with droxidopa

20. Currently receiving any investigational drug or have received an investigational drug
within 30 days of the baseline visit (Visit 2)

21. Any condition or laboratory test result, which in the Investigator's judgment, might
result in an increased risk to the patient, or would affect their participation in
the study. Additionally the Investigator has the ability to exclude a patient if for
any reason they feel the subject is not a good candidate for the study or will not be
able to follow study procedures.